Core Problem Statement

Conventional vaccine manufacturing models face strict cold-chain dependencies, limited multi-variant profiling capabilities, and slow synthesis cycles, significantly hindering rapid pandemic responses within resource-limited zones.

Solution Overview

A patented Multimeric Self-assembling Nanocage platform architecture enabling plug-and-play multivalent antigen display via economical bacterial expression systems. The technology powers a proprietary thermostable next-generation Mpox vaccine alongside pan-betacoronavirus candidates utilizing cross-variant epitopes for broad protective durability.

Strategic Engagement Opportunities

The MSN platform offers biological manufacturers, global healthcare networks, and vaccine research groups structured technology transfer models and co-development pathways optimized for low-cost, decentralized regional deployments.